Shanghai Yizhong Pharmaceutical Valuation
Is 688091 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688091?
Other financial metrics that can be useful for relative valuation.
| What is 688091's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | CN¥12.64b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 48.8x |
| Enterprise Value/EBITDA | 99.3x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 688091's PE Ratio compare to its peers?
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 46.4x | ||
688578 Shanghai Allist Pharmaceuticals | 84.4x | n/a | CN¥11.2b |
300181 Zhejiang Jolly PharmaceuticalLTD | 3.3x | n/a | CN¥9.7b |
688356 Jenkem Technology | 51.6x | 38.3% | CN¥9.4b |
300573 Shenyang Xingqi PharmaceuticalLtd | 46.1x | n/a | CN¥11.1b |
688091 Shanghai Yizhong Pharmaceutical | 88.5x | n/a | CN¥12.6b |
Price to Earnings Ratio vs Industry
How does 688091's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price to Earnings Ratio vs Fair Ratio
What is 688091's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 88.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 688091's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 688091 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?